Expertise in
14
conditions

Roland Meisel

Duesseldorf, NW, DE 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
14
conditions
Duesseldorf, NW, DE 

Overview

Roland Meisel practices practicing medicine in Duesseldorf, Germany.

Mr. Meisel is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Hemoglobinopathy, Anemia, Bone Marrow Transplant, and Bone Graft.

He is actively involved in clinical research, co-authoring 123 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Duesseldorf, NW, Germany
Other Locations
Heidelberg, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Treatment of Chemo-refractory Viral Infections After Allogeneic Stem Cell Transplantation With Multispecific T Cells Against CMV, EBV and AdV: A Phase III, Prospective, Multicentre Clinical Trial
Treatment of Chemo-refractory Viral Infections After Allogeneic Stem Cell Transplantation With Multispecific T Cells Against CMV, EBV and AdV: A Phase III, Prospective, Multicentre Clinical Trial
Enrollment Status: Recruiting
Publish Date: July 18, 2025
Intervention Type: Other
Study Phase: Phase 3
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Enrollment Status: Recruiting
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: VP16, Thiotepa, Treosulfan, Fludarabine, Busulfan, Anti-Thymocyte Globulin, Cyclophosphamide, Grafalon
Study Phase: Phase 2/Phase 3

123 Total Publications

First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.
First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 06, 2026

Frequently Asked Questions about Roland Meisel

Is Roland Meisel a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Roland Meisel is classified as an Distinguished expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Roland Meisel participate in research or clinical trials?

Yes. Roland Meisel has published 123 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Roland Meisel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Meisel's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 31 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile